Cargando…
A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model
An estimated 417 million people worldwide ages 15 to 49 are infected with herpes simplex virus type 2 (HSV-2), the most common cause of genital ulcer disease. Some individuals experience frequent recurrences of genital lesions, while others only have subclinical infection, yet all risk transmitting...
Autores principales: | Awasthi, Sita, Hook, Lauren M., Shaw, Carolyn E., Friedman, Harvey M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718817/ https://www.ncbi.nlm.nih.gov/pubmed/28481687 http://dx.doi.org/10.1080/21645515.2017.1323604 |
Ejemplares similares
-
Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection
por: Egan, Kevin, et al.
Publicado: (2020) -
An mRNA vaccine to prevent genital herpes
por: Awasthi, Sita, et al.
Publicado: (2022) -
Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs
por: Hook, Lauren M., et al.
Publicado: (2018) -
An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs
por: Awasthi, Sita, et al.
Publicado: (2017) -
An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection
por: Egan, Kevin P., et al.
Publicado: (2020)